NCCN Receives $1 Million Grant From Genentech
PHILADELPHIA--The NCCN (National Comprehensive Cancer Network) has received a $1 million unrestricted grant from Genentech, Inc. The grant, provided over a 2-year period, will be used to support the development and expansion of the NCCN Oncology Outcomes Database with emphasis on breast cancer and non-Hodgkin’s lymphoma.
PHILADELPHIA--The NCCN (National Comprehensive Cancer Network) has received a $1 million unrestricted grant from Genentech, Inc. The grant, provided over a 2-year period, will be used to support the development and expansion of the NCCN Oncology Outcomes Database with emphasis on breast cancer and non-Hodgkins lymphoma.
The NCCN, established in 1995, is a coalition of 17 leading US cancer centers. To date, the network has developed Oncology Practice Guidelines, which are steadily becoming the standard for clinical and coverage policy in cancer care. To date, NCCN guidelines are available for 93% of all cancers.
The NCCN Oncology Outcomes Database was launched recently in an effort to provide patients, physicians, and payers with a constant flow of data and information to facilitate optimal decision-making in the treatment of all cancers.
"This agreement with Genentech affirms the critical importance of the NCCNs Oncology Outcomes Database, as well as NCCNs commitment to the highest quality of cancer care through excellence in research and the collection and analysis of outcomes data," said
NCCN chief executive officer William T. McGivney, PhD, commented, "NCCN implementation of practice guidelines through performance measurement establishes the model for continuous quality improvement in cancer care."
